PD173074 

PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer^[1][2][3].

PD173074 GMP (GMP) (100 nmol/L; 3-hour pre-incubation, followed by 10-day incubation with repeated 3-hour pre-incubations every 3 days) blocks FGF-induced endothelial differentiation of human adipose-derived stem cells, including reducing CD31 and eNOS mRNA expression, preventing capillary-like structure formation on Matrigel, and eliminating eNOS protein expression^[1].
PD173074 GMP (GMP) (200 nM; 6 h) upregulates LEFTY1, LEFTY2, and FST and downregulates CRIPTO, NODAL, INHBA, INHBB, and NANOG in on-feeder human iPSCs, with no effect on NOMO1, NOMO2, NOMO3, NCLN, or OCT4^[2].
PD173074 GMP (GMP) (200 nM; 6 h) downregulates LEFTY1, NODAL, and NANOG and upregulates FST in feeder-less human iPSCs, with no effect on CRIPTO, LEFTY2, or OCT4^[2].
PD173074 GMP (GMP) (200 nM; 2-6 h) induces time-dependent downregulation of LEFTY1 (starting at 2 h), NODAL (at 6 h), LEFTY2 (at 6 h), and NANOG (starting at 4 h) in feeder-less human iPSCs, with no effect on CRIPTO or OCT4 over 6 h^[2].
PD173074 GMP (GMP) (200 nM; 24 h) downregulates CRIPTO, LEFTY1, and NANOG in feeder-less human iPSCs^[2].
PD173074 GMP (GMP) (200 nM; 6 h) reduces phosphorylation of SMAD2 and FGFR in feeder-less human iPSCs, with no effect on total SMAD2/3 or CRIPTO protein levels^[2].
PD173074 GMP (GMP) (200 nM; 6 h) does not change the perinuclear localization of CRIPTO in feeder-less human iPSCs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PD173074 GMP (50 mg/kg; p.o.; once daily; 28 d) inhibits the growth of xenograft tumors in nude mouse models inoculated with H-510 and H-69 human small cell lung cancer cells, and its efficacy is comparable to that of Cisplatin (HY-17394) in the H-510 model^[3].
PD173074 GMP (50 mg/kg; p.o.; once daily; 14 d): In nude mouse models inoculated with H-69 human small cell lung cancer cells, it reduces intratumoral proliferation in the early stage of treatment, and this change can be detected by [¹⁸F] FLT-PET in vivo imaging between 7 and 14 days of treatment^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

523.67

C₂₈H₄₁N₇O₃

219580-11-7

O=C(NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C3=CC(OC)=CC(OC)=C3)NC(C)(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Khan S, et al. Fibroblast growth factor and vascular endothelial growth factor play a critical role in endotheliogenesis from human adipose-derived stem cells. J Vasc Surg. 2017;65(5):1483-1492.

  [2]. Wakitani S. The FGF receptor inhibitor PD173074 modulates Lefty expression in human induced pluripotent stem cells differently depending on the culture conditions[J]. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2022, 1869(7): 119260.

  [3]. Pardo O E, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo[J]. Cancer research, 2009, 69(22): 8645-8651.